S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
NASDAQ:TLRY

Tilray Stock Forecast, Price & News

$6.29
-0.57 (-8.31%)
(As of 01/18/2022 04:00 PM ET)
Add
Compare
Today's Range
$6.27
$6.79
50-Day Range
$6.29
$13.03
52-Week Range
$6.27
$67.00
Volume
21.65 million shs
Average Volume
31.95 million shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.39
30 days | 90 days | 365 days | Advanced Chart
Receive TLRY News and Ratings via Email

Sign-up to receive the latest news and ratings for Tilray and its competitors with MarketBeat's FREE daily newsletter.


Tilray logo

About Tilray

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TLRY
Fax
N/A
Employees
2,100
Year Founded
N/A

Sales & Book Value

Annual Sales
$513.09 million
Book Value
$9.98 per share

Profitability

Net Income
$-367.42 million
Pretax Margin
-67.24%

Debt

Price-To-Earnings

Miscellaneous

Free Float
452,714,000
Market Cap
$2.90 billion
Optionable
Optionable

Company Calendar

Last Earnings
1/10/2022
Today
1/18/2022
Next Earnings (Estimated)
5/09/2022
Fiscal Year End
5/31/2022

MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

973rd out of 1,414 stocks

Medicinals & Botanicals Industry

8th out of 19 stocks

Analyst Opinion: 3.1Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Tilray (NASDAQ:TLRY) Frequently Asked Questions

Is Tilray a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Tilray stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TLRY, but not buy additional shares or sell existing shares.
View analyst ratings for Tilray
or view top-rated stocks.

How has Tilray's stock been impacted by Coronavirus (COVID-19)?

Tilray's stock was trading at $7.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TLRY shares have decreased by 11.3% and is now trading at $6.29.
View which stocks have been most impacted by COVID-19
.

When is Tilray's next earnings date?

Tilray is scheduled to release its next quarterly earnings announcement on Monday, May 9th 2022.
View our earnings forecast for Tilray
.

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) posted its quarterly earnings data on Monday, January, 10th. The company reported $0.03 EPS for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.12. The firm had revenue of $155.10 million for the quarter, compared to the consensus estimate of $171.57 million. Tilray had a negative net margin of 66.64% and a negative trailing twelve-month return on equity of 2.57%. The company's quarterly revenue was up 19.8% on a year-over-year basis.
View Tilray's earnings history
.

What price target have analysts set for TLRY?

13 brokers have issued 1 year price objectives for Tilray's stock. Their forecasts range from $7.00 to $23.00. On average, they expect Tilray's stock price to reach $12.54 in the next year. This suggests a possible upside of 99.4% from the stock's current price.
View analysts' price targets for Tilray
or view top-rated stocks among Wall Street analysts.

Who are Tilray's key executives?

Tilray's management team includes the following people:
  • Mr. Edward Wood Pastorius Jr., Chief Revenue Officer (Age 50)
  • Mr. Brendan Kennedy, Pres, CEO & Director (Age 46)
  • Mr. Mark Castaneda, CFO, Sec. & Treasurer (Age 53)
  • Dr. Catherine Jacobson, Director of Clinical Research & Member of Medical Advisory Board

What is Brendan Kennedy's approval rating as Tilray's CEO?

32 employees have rated Tilray CEO Brendan Kennedy on Glassdoor.com. Brendan Kennedy has an approval rating of 51% among Tilray's employees. This puts Brendan Kennedy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Square (SQ).

When did Tilray IPO?

(TLRY) raised $135 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

What is Tilray's stock symbol?

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Who are Tilray's major shareholders?

Tilray's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cutler Group LP (0.00%), Polianta Ltd (0.03%), Wedbush Securities Inc. (0.01%), Stratos Wealth Partners LTD. (0.00%), Grassi Investment Management (0.00%) and Exchange Traded Concepts LLC (0.00%). Company insiders that own Tilray stock include Brendan Kennedy, Carl A Merton, Christine StClare, James R Meiers, Maryscott Greenwood and Michael Auerbach.
View institutional ownership trends for Tilray
.

Which institutional investors are selling Tilray stock?

TLRY stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP, Grassi Investment Management, Wedbush Securities Inc., Koshinski Asset Management Inc., Stratos Wealth Partners LTD., and IFP Advisors Inc. Company insiders that have sold Tilray company stock in the last year include Brendan Kennedy, Carl A Merton, and James R Meiers.
View insider buying and selling activity for Tilray
or view top insider-selling stocks.

Which institutional investors are buying Tilray stock?

TLRY stock was purchased by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, Polianta Ltd, and Clear Street Markets LLC.
View insider buying and selling activity for Tilray
or or view top insider-buying stocks.

How do I buy shares of Tilray?

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tilray's stock price today?

One share of TLRY stock can currently be purchased for approximately $6.29.

How much money does Tilray make?

Tilray has a market capitalization of $2.90 billion and generates $513.09 million in revenue each year. The company earns $-367.42 million in net income (profit) each year or ($1.91) on an earnings per share basis.

How many employees does Tilray have?

Tilray employs 2,100 workers across the globe.

What is Tilray's official website?

The official website for Tilray is www.tilray.com.

Where are Tilray's headquarters?

Tilray is headquartered at 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2.

How can I contact Tilray?

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The company can be reached via phone at 206-432-9325.


This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.